Overview

An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.

Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells that stably express multiplexed shRNA to treat HIV infection.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Public Health Clinical Center
Collaborators:
Kanglin Biotech (Hangzhou) Co. LTD
R&D Kanglin Biotech
Treatments:
Busulfan